Explanipedia

Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab Open

Sonya Chew, Emanuela Ferraro, Y. Chen, Andrea V. Barrio, Daniel J. Kelly , et al. · 2024

Patients with HER2(+) early breast cancer (EBC) receiving neoadjuvant systemic therapy (NAST) have poorer outcomes if they have residual disease (RD). We analyzed IDFS and brain metastasis (BM) rates in patients with HER2(+) EBC treated wi…

UK multicentre real-world data of the use of cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer Open

G. Gullick, C.N. Owen, William J. Watkins, Seamus Cook, J. Helbrow , et al. · 2024

Background \nCyclin-dependent kinase 4/6 inhibitors (CDK4/6is) are widely used to treat hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC). This study aimed to capture …

Quality of life in women with early-stage and metastatic hormone receptor-positive, HER2-negative breast cancer receiving endocrine therapy Open

David O’Reilly, Abdul Rehman Farooq, Paul Nevins Selvadurai, Laura Sheehan, Karen Molan , et al. · 2024

Introduction Early discontinuation of endocrine therapy (ET) is higher among patients with early breast cancer (EBC) compared to patients with metastatic hormone receptor-positive (HR+) breast cancer (MBC). In our clinical experience the r…

Impact of Cyclin Dependent Kinase 4/6 Inhibitors on Breast Cancer Brain Metastasis Outcomes Open

Sonya Chew, Emanuela Ferraro, Anton Safanov, Yuan Chen, Daniel W. Kelly , et al. · 2024

Invasive Disease Free Survival and Brain Metastasis Rates in Patients Treated with Neoadjuvant Chemotherapy with Trastuzumab and Pertuzumab Open

Chau T. Dang, Sonya Chew, Emanuela Ferraro, Yuan Chen, Andrea V. Barrio , et al. · 2023

Background: Patients (pts) with human epidermal growth factor receptor 2 (HER2) positive (+) early breast cancer (EBC) receiving neoadjuvant systemic therapy (NAST) have poorer outcomes if they have residual disease (RD) after surgery. HER…

291P Prognostic implications of HER2 gain in patients with HR+/HER2- breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC) Open

Emanuela Ferraro, Sonya Chew, Dmitry Nemirovsky, Ye Chen, A.V. Barrio , et al. · 2023

Serum interleukin-4 is elevated in clinical drug-induced liver injury Open

M N Liu, Maggie Au, M Bishara, Thomas Worland, Danny Con , et al. · 2023

Drug-induced liver injury (DILI) remains a challenging diagnosis due to an absence of specific biomarkers. DILI due to volatile anaesthetics (VA-DILI) is characterised by trifluoroacetyl and CYP2E1 antibodies, but may not be seen for weeks…

Impact of prior systemic therapy on lymphocytic infiltration in surgically resected breast cancer brain metastases Open

Sonya Chew, Andrew Bacotti, Y. Chen, Carey K. Anders, Maria J. Sambade , et al. · 2023

Characterization of Treatments and Disease Course for Women with Breast Cancer Brain Metastases: 5-Year Retrospective Single Institution Experience Open

Sonya Chew, Hailey Carroll, Waseem Darwish, Oleksandr Boychak, Michaela J. Higgins , et al. · 2021

After BM development, half of the patients had systemic therapy and 70% had local therapy, but only the HER2 subgroup had a prolonged OS likely reflecting central nervous system (CNS) activity of anti-HER2 drugs. TNBC patients had the wors…

SKAP2-BRAF fusion and response to an MEK inhibitor in a patient with metastatic melanoma resistant to immunotherapy Open

Sonya Chew, Mairi Lucas, Michelle M. Brady, Catherine M. Kelly · 2021

A woman in her 40s presented to the emergency department with headache and unintentional weight loss in September 2018. Investigations revealed a widely metastatic pan-negative melanoma of unknown primary. She had multiple lines of treatme…

TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer Open

Karen Slattery, Elena Woods, Vanessa Zaiatz-Bittencourt, Sam Jonathan Marks, Sonya Chew , et al. · 2021

Background Natural killer (NK) cells provide important immune protection from cancer and are a key requirement for particular immunotherapies. There is accumulating evidence that NK cells become dysfunctional during cancer. Overcoming NK c…

Virtual oncology clinics during the COVID-19 pandemic Open

David O’Reilly, Hailey Carroll, Mairi Lucas, Jane Sze Yin Sui, Maha Al Sendi , et al. · 2021

TGFβ drives mitochondrial dysfunction in peripheral blood NK cells during metastatic breast cancer Open

Karen Slattery, Vanessa Zaiatz-Bittencourt, Elena Woods, Kiva Brennan, Sam Jonathan Marks , et al. · 2019

Natural Killer (NK) cells provide important protection from cancer and are a key requirement for particular immunotherapies. In activated NK cells, a metabolic response towards increased glycolysis and oxidative phosphorylation is crucial …

Unusual Sites of High-Grade Neuroendocrine Carcinomas: A Case Series and Review of the Literature Open

Geoffrey Alan Watson, Yasar Ahmed, Sarah Picardo, Sonya Chew, Shona Cobbe , et al. · 2018

BACKGROUND Neuroendocrine tumors (NETs) encompass a diverse group of varying clinicopathological entities arising from cells of the endocrine and nervous systems. The presentation of these unique tumors can range from occult disease discov…

A Patient with Testicular Seminoma, Inguinal Lymphadenopathy and Abnormal Pet Scan Open

Rajnish Kumar Gupta, Sonya Chew, Geoffrey Alan Watson, Sarah Picardo, Vourneen Healy · 2017

Testicular malignancies are rare but are associated with an excellent prognosis. The majority of patients are diagnosed at an early stage, and even in the presence of nodal or distant metastases, treatment is administered with curative int…

Sonya Chew YOU? Author Swipe